<i id='1F15DDED14'><strike id='1F15DDED14'><tt id='1F15DDED14'><pre id='1F15DDED14'></pre></tt></strike></i> 
EQRx is done, sold for its cash.
The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
advertisement
The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
In age of alternative facts, a scholarly course on calling out crap 
Ancient Greek ideas underpin modern concepts of pregnancy 
Peter Hotez and the public health issue of online harassment 
For AI in health care standards, federal regulators join with industry group 
Affirmative action in medical school literally saved lives 
IVF doctors demand details after CooperSurgical lawsuit 
Activists slam private health insurers over coverage restrictions 
Medicare drug price negotiation continues, as pharma counteroffers 
Apple is now the first public company to be valued at $3 trillion 
Longer MASH drug regimen improved liver, Akero study finds 
George Santos makes 1st court appearance after pleading not guilty to 13 counts 
Streamlined flu vaccines recommended by FDA advisory panel 
DIEP, the 'gold standard' of breast reconstruction, is under threat 
Biden's 'march 
As demand for Covid shots wanes, Moderna seeks its next success 
